

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Zhaoke Ophthalmology Limited**  
**兆科眼科有限公司**

*(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)*  
**(Stock Code: 6622)**

**VOLUNTARY ANNOUNCEMENT –**  
**COMPLETION OF NVK002 PHASE III MINI-CHAMP**  
**LAST PATIENT LAST VISIT IN CHINA**

This announcement is made by the board of directors (the “**Board**”) of Zhaoke Ophthalmology Limited (the “**Company**”) on a voluntary basis.

The Board of the Company is pleased to announce that the last patient last visit was completed for the one-year Phase III bridging clinical trial (“**Mini-CHAMP**”) of one of the Company’s core products, NVK002 for the treatment of myopia, on August 3, 2023.

The Company has been conducting a parallel two-year Phase III clinical trial (“**China CHAMP**”). The main objective of China CHAMP and Mini-CHAMP is to evaluate the efficacy and safety of NVK002 (low dose atropine 0.01% and 0.02%) in the treatment of myopia progression in children and adolescents in Chinese population. The China CHAMP trial involves 18 centers and enrolled 777 patients; The Mini-CHAMP trial involved 16 centers and enrolled 526 patients. The completion of Mini-CHAMP’s last patient last visit is an important step forward to the Company’s submission of New Drug Application (“**NDA**”) in China.

On June 7, 2023, the Company announced that its partner – Vyluma Inc. (“**Vyluma**”) had announced that the U.S. Food and Drug Administration (“**FDA**”) has accepted for review the New Drug Application (“**NDA**”) for NVK002 (low dose atropine 0.01%) as a potential treatment for myopia in children. NVK002 is currently positioned as the first clinically-proven pharmaceutical product approved for treating the progression of myopia in the world.

## **ABOUT NVK002**

NVK002 is an investigational novel topical ophthalmic solution to control myopia progression in children and adolescents. NVK002 has a proprietary formulation that successfully addresses the instability of low-concentration atropine, this technology has intellectual property protection globally. It is preservative-free with an expected shelf life of over 24 months. According to information from China Insights Consultancy (“CIC”), NVK002 is currently one of the most advanced atropine drug candidates globally for treating myopia progression, and targets the broadest patient group, covering children and adolescents from 3 to 17 years old.

The clinical development of NVK002 involves two different concentrations of atropine to allow flexibility in achieving maximal efficacy and minimal adverse effects for tailoring to the needs of individual patients.

## **ABOUT THE LICENSE AGREEMENT WITH VYLUMA INC.**

In October 2020, the Company entered into a license agreement, namely the NVK002 License Agreement, with Nevakar Inc., which later assigned the agreement to its wholly-owned subsidiary, Vyluma Inc. for an exclusive license to develop, manufacture, register, import and commercialize NVK002 in Greater China, South Korea and certain countries in Southeast Asia (including Brunei, Burma, Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand and Vietnam). For details of the license agreement in relation to NVK002, please refer to “Business – Collaboration and License Agreements – License of NVK002” of the prospectus of the Company dated April 16, 2021.

**Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately commercialize NVK002 successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Zhaoke Ophthalmology Limited**  
**Dr. Li Xiaoyi**  
*Chairman*

Hong Kong, August 9, 2023

*As at the date of this announcement, the Board comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors, Ms. Leelalertsuphakun Wanee, Ms. Tiantian Zhang, Ms. Cai Li and Mr. Chen Yu as non-executive Directors, and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.*